Comparison of the effectiveness of recombinant human growth hormone therapy in preterm and full-term children with short stature born small for gestational age

Purpose With improvements in the infant survival rates for high-risk pregnancies, the prevalence of short stature in children born prematurely and small for gestational age (SGA) has also increased. The aim of this study was to compare the effectiveness of recombinant human growth hormone (rhGH) the...

Full description

Saved in:
Bibliographic Details
Main Authors: Dohyung Kim, Ji-Hee Yoon, Soojin Hwang, Ja Hye Kim, Han-Wook Yoo, Jin-Ho Choi
Format: Article
Language:English
Published: Korean Society of Pediatric Endocrinology 2025-06-01
Series:Annals of Pediatric Endocrinology & Metabolism
Subjects:
Online Access:http://e-apem.org/upload/pdf/apem-2448128-064.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849424837107253248
author Dohyung Kim
Ji-Hee Yoon
Soojin Hwang
Ja Hye Kim
Han-Wook Yoo
Jin-Ho Choi
author_facet Dohyung Kim
Ji-Hee Yoon
Soojin Hwang
Ja Hye Kim
Han-Wook Yoo
Jin-Ho Choi
author_sort Dohyung Kim
collection DOAJ
description Purpose With improvements in the infant survival rates for high-risk pregnancies, the prevalence of short stature in children born prematurely and small for gestational age (SGA) has also increased. The aim of this study was to compare the effectiveness of recombinant human growth hormone (rhGH) therapy for preterm and full-term SGA children with short stature. Methods This study included 114 children born SGA (40 preterm and 74 term), who showed no catch-up growth by age 4 years and had undergone rhGH therapy for at least one year. The clinical parameters were reviewed retrospectively. Results The mean height standard deviation scores (SDSs) for preterm and full-term SGA children at the start of rhGH therapy were -2.97±0.85 and -2.46±0.54, respectively. The mean duration of treatment was 3.3±1.9 years for preterm SGA children and 3.3±1.6 years for full-term SGA children. The height SDS increased to -1.13±0.96 in preterm children and -0.77±0.59 in full-term children by the fourth year of treatment. Full-term SGA children responded better to rhGH therapy than preterm children in the first year of therapy (P=0.03). Serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 levels significantly increased after the start of rhGH therapy (P<0.001). Conclusions rhGH therapy significantly improved height SDS in both preterm and full-term SGA children, emphasizing the key role of this intervention for managing short stature in children born SGA, regardless of gestational age.
format Article
id doaj-art-ba33e254caef40d8aacccf2d80e097dc
institution Kabale University
issn 2287-1012
2287-1292
language English
publishDate 2025-06-01
publisher Korean Society of Pediatric Endocrinology
record_format Article
series Annals of Pediatric Endocrinology & Metabolism
spelling doaj-art-ba33e254caef40d8aacccf2d80e097dc2025-08-20T03:29:58ZengKorean Society of Pediatric EndocrinologyAnnals of Pediatric Endocrinology & Metabolism2287-10122287-12922025-06-0130314014810.6065/apem.2448128.0641103Comparison of the effectiveness of recombinant human growth hormone therapy in preterm and full-term children with short stature born small for gestational ageDohyung Kim0Ji-Hee Yoon1Soojin Hwang2Ja Hye Kim3Han-Wook Yoo4Jin-Ho Choi5 Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaPurpose With improvements in the infant survival rates for high-risk pregnancies, the prevalence of short stature in children born prematurely and small for gestational age (SGA) has also increased. The aim of this study was to compare the effectiveness of recombinant human growth hormone (rhGH) therapy for preterm and full-term SGA children with short stature. Methods This study included 114 children born SGA (40 preterm and 74 term), who showed no catch-up growth by age 4 years and had undergone rhGH therapy for at least one year. The clinical parameters were reviewed retrospectively. Results The mean height standard deviation scores (SDSs) for preterm and full-term SGA children at the start of rhGH therapy were -2.97±0.85 and -2.46±0.54, respectively. The mean duration of treatment was 3.3±1.9 years for preterm SGA children and 3.3±1.6 years for full-term SGA children. The height SDS increased to -1.13±0.96 in preterm children and -0.77±0.59 in full-term children by the fourth year of treatment. Full-term SGA children responded better to rhGH therapy than preterm children in the first year of therapy (P=0.03). Serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 levels significantly increased after the start of rhGH therapy (P<0.001). Conclusions rhGH therapy significantly improved height SDS in both preterm and full-term SGA children, emphasizing the key role of this intervention for managing short stature in children born SGA, regardless of gestational age.http://e-apem.org/upload/pdf/apem-2448128-064.pdfgrowth hormoneprematurityshort staturesmall for gestational age
spellingShingle Dohyung Kim
Ji-Hee Yoon
Soojin Hwang
Ja Hye Kim
Han-Wook Yoo
Jin-Ho Choi
Comparison of the effectiveness of recombinant human growth hormone therapy in preterm and full-term children with short stature born small for gestational age
Annals of Pediatric Endocrinology & Metabolism
growth hormone
prematurity
short stature
small for gestational age
title Comparison of the effectiveness of recombinant human growth hormone therapy in preterm and full-term children with short stature born small for gestational age
title_full Comparison of the effectiveness of recombinant human growth hormone therapy in preterm and full-term children with short stature born small for gestational age
title_fullStr Comparison of the effectiveness of recombinant human growth hormone therapy in preterm and full-term children with short stature born small for gestational age
title_full_unstemmed Comparison of the effectiveness of recombinant human growth hormone therapy in preterm and full-term children with short stature born small for gestational age
title_short Comparison of the effectiveness of recombinant human growth hormone therapy in preterm and full-term children with short stature born small for gestational age
title_sort comparison of the effectiveness of recombinant human growth hormone therapy in preterm and full term children with short stature born small for gestational age
topic growth hormone
prematurity
short stature
small for gestational age
url http://e-apem.org/upload/pdf/apem-2448128-064.pdf
work_keys_str_mv AT dohyungkim comparisonoftheeffectivenessofrecombinanthumangrowthhormonetherapyinpretermandfulltermchildrenwithshortstaturebornsmallforgestationalage
AT jiheeyoon comparisonoftheeffectivenessofrecombinanthumangrowthhormonetherapyinpretermandfulltermchildrenwithshortstaturebornsmallforgestationalage
AT soojinhwang comparisonoftheeffectivenessofrecombinanthumangrowthhormonetherapyinpretermandfulltermchildrenwithshortstaturebornsmallforgestationalage
AT jahyekim comparisonoftheeffectivenessofrecombinanthumangrowthhormonetherapyinpretermandfulltermchildrenwithshortstaturebornsmallforgestationalage
AT hanwookyoo comparisonoftheeffectivenessofrecombinanthumangrowthhormonetherapyinpretermandfulltermchildrenwithshortstaturebornsmallforgestationalage
AT jinhochoi comparisonoftheeffectivenessofrecombinanthumangrowthhormonetherapyinpretermandfulltermchildrenwithshortstaturebornsmallforgestationalage